STOCKS TELEGRAPH

Category: Mid Day Movers

  • Soleno Therapeutics (SLNO) Stock Gains Traction With Recent Regulatory Approvals

    Soleno Therapeutics (SLNO) Stock Gains Traction With Recent Regulatory Approvals

    Soleno Therapeutics, Inc. (NASDAQ: SLNO) stock is witnessing a remarkable surge of 19.95% in its shares, trading at $45.45 as of the last check during current market. This noteworthy upswing of SLNO stock on the US charts is directly attributable to regulatory greenlights.

    Today, Soleno Therapeutics (SLNO) announced that diazoxide choline has been designated as a breakthrough therapy by the U.S. Food and Drug Administration (FDA). This classification is for the therapeutic intervention of adults and children four years of age and older with hyperphagia and genetically proven Prader-Willi syndrome (PWS).

    The conferment of this designation underscores the Agency’s discernment that, based on an evaluation of preliminary data emanating from the Phase 3 clinical development program, diazoxide choline exhibits the potential for substantial enhancement on clinically significant endpoint(s) compared to existing therapies.

    This milestone, marked by the grant of Breakthrough Therapy Designation, signifies a significant advancement for Soleno Therapeutics’ DCCR clinical development initiative, notably as the first such designation for a drug aimed at PWS treatment.

    This pivotal designation serves as affirmation of the FDA’s recognition of PWS as a severe medical condition and indicates the promising prospects of DCCR as a safe and efficacious therapeutic intervention for PWS. SLNO remains steadfast in its commitment to preparing the NDA submission for DCCR in PWS, with an anticipated timeframe around mid-2024.

    The FDA’s Breakthrough Therapy Designation is tailored to accelerate the development and evaluation processes of drugs in the U.S. designated for the treatment of severe medical conditions, particularly when initial clinical data suggests significant improvements over existing therapies on clinically relevant parameters.

    By bestowing Breakthrough Therapy Designation, the FDA facilitates comprehensive guidance and institutional dedication involving senior management in a proactive, collaborative, interdisciplinary review process, potentially enabling priority review and other measures to expedite assessment.

    Diazoxide choline holds Orphan Drug Designation for PWS in both the U.S. and E.U., along with Fast Track Designation in the U.S.

  • Phibro Animal Health (PAHC): Unprecedented Stock Surge And Strategic Acquisition

    Phibro Animal Health (PAHC): Unprecedented Stock Surge And Strategic Acquisition

    Phibro Animal Health Corporation (NASDAQ: PAHC) is on bullish trend during the current market trading today, marking a substantial increase of 29.41% to reach a valuation of $16.47. This upswing in PAHC stock follows an asset acquisition agreement.

    Phibro Animal Health (PAHC) announced today that it and Zoetis Inc. (NYSE: ZTS) have entered into a final agreement. PAHC will pay $350 million, subject to normal closing adjustments, to acquire Zoetis’ medicated feed additive (MFA) product array, certain water soluble products, and related assets.

    It is anticipated that this deal would close in the second half of 2024. Zoetis and Phibro Animal Health both have a long history of commitment to the production animal health industry. The product assortment that was bought generated around $400 million in revenue in 2023 and consists of more than 37 product variants that are sold in almost 80 different countries.

    Moreover, the agreement encompasses six manufacturing facilities, with four situated in the U.S., one in Italy, and one in China. It is foreseen that over 300 Zoetis employees involved in manufacturing, distribution, and commercial operations will transition to Phibro Animal Health.

    This transaction underscores Zoetis’ disciplined approach to capital allocation, prioritizing investments in animal health, productivity, and sustainability solutions. Through this divestiture, Zoetis can redirect its livestock investments towards other solutions, encompassing vaccine, biologic, and genetic programs.

    Zoetis’ robust portfolio of MFA and water soluble products spanning cattle, swine, and poultry will complement and broaden Phibro Animal Health’s species and product portfolios, aiding customers in meeting the most stringent standards of animal welfare, disease prevention, and nutritional enhancement.

    If the acquisition’s effects were taken into account, Phibro Animal Health would have had revenues of about $1.4 billion during the previous year. The acquisition is set to be primarily financed through debt, with Phibro Animal Health securing financing commitments from several key banking partners.

    Over an extensive timeframe, Zoetis has established a valuable, top-tier, and dependable source of medicated feed additives worldwide. The asset acquisition will serve to enrich, diversify, and expand PAHC’s global portfolio.

  • Acquisition Deal Propel Deciphera Pharmaceuticals (DCPH) Shares

    Acquisition Deal Propel Deciphera Pharmaceuticals (DCPH) Shares

    Over the course of today’s current session, Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) has seen a remarkable 72.39% increase in share price, closing at $25.25. The announcement of a proposed acquisition of Deciphera Pharmaceuticals has resulted in a notable surge in the value of DCPH shares on US stock markets.

    Deciphera Pharmaceuticals (DCPH) made a formal announcement today announcing the signing of a final merger agreement with ONO Pharmaceutical Co., Ltd. (ONO). In line with the terms of this agreement, ONO will buy all outstanding shares of Deciphera common stock for $25.60 per share in cash.

    The $2.4 billion total equity value of the purchase process will be reached through a tender offer, which will be followed by the merger of Deciphera Pharmaceuticals with an ONO wholly-owned subsidiary. The combined venture between ONO and Deciphera Pharmaceuticals aims to expedite their mutual goal of creating innovative drugs for worldwide patient care.

    A number of potential first- or best-in-class medications, such as vimseltinib, the ULK inhibitor DCC-3116, and other cancer prospects, are part of DCPH’s well-developed and diversified pipeline. With encouraging key clinical evidence, the highly selective switch-control kinase inhibitor imeltinib has established itself as a possible first-line and innovative treatment for tenosynovial giant cell tumors (TGCT) and maybe additional indications.

    In accordance with the provisions of the final merger agreement, ONO will pay $25.60 per share in cash to acquire all of the existing Deciphera shares, for an estimated total equity value of $2.4 billion. The acquisition price represents a premium of 68.8% over the volume weighted average price of Deciphera Pharmaceuticals as of April 26, 2024, and a premium of 74.7% over DCPH’s closing price of $14.65 on the same day.

    With this purchase, ONO should be better equipped to strengthen its position in oncology, one of its main areas of focus, and to further its goals of becoming a Global Specialty Pharma company. The purchase structure calls for a tender offer, which is followed by a merger of Deciphera Pharmaceuticals with an ONO subsidiary that is completely owned.

  • OptimizeRx (OPRX) Stock Valuation Soars: Insights Unveiled

    OptimizeRx (OPRX) Stock Valuation Soars: Insights Unveiled

    OptimizeRx Corp. (NASDAQ: OPRX) shares surged 14.32% to $10.06 on US stock exchanges today. The current-market rise followed a business update and preliminary financial results announcement, attracting attention from analysts and investors.

    OptimizeRx (OPRX) has released preliminary, unaudited financial statistics for many key performance indicators (KPIs) for the first quarter of 2024 in addition to a comprehensive business update.

    According to projections, OptimizeRx expects first-quarter sales to increase by more than 40% year over year, with statistics predicted to fall between $18.5 million and $19.2 million. The momentum gained in the fourth quarter has seamlessly transitioned into the first quarter of 2024, evidenced by the procurement of 9 new Dynamic Audience Activation Platform (DAAP) agreements.

    Present market trends align favorably with OptimizeRx’s strategic approach, as pharmaceutical entities increasingly seek partnerships with scalable platforms possessing agile precision-marketing capabilities, which epitomizes the core functionality of its AI-enabled platform.

    Furthermore, the commercial integration efforts between OptimizeRx and Medicx are progressing ahead of schedule, presenting numerous new cross-selling opportunities currently in advanced negotiation stages.

    The amalgamation of the two entities is proceeding expediently, positioning OptimizeRx as the sole scalable platform with comprehensive reach encompassing both healthcare providers (HCPs) and direct-to-consumer channels.

    This distinctive market positioning amplifies OPRX’s capacity for cross-selling and upselling endeavors, unlocking considerable value. OptimizeRx estimates the potential revenue opportunity solely from existing brands to be approximately $2.8 billion, with even greater prospects for brands not yet supported by the company.

    Moreover, the 2024 report on Environmental, Social, and Governance (ESG) activities by OptimizeRx was just released. As a pioneer in health technology, OptimizeRx continues to be unwavering in its commitment to balancing its purpose with corporate responsibility by enabling vital interactions between life sciences, healthcare professionals, and patients.

    Stakeholders prioritize a company’s dedication to ESG responsibilities, prompting OptimizeRx to persist in fostering constructive changes and embedding sustainable practices across the organization. OptimizeRx pledges to evolve with the dynamic world, showcasing ongoing enhancements and transparently documenting ESG endeavors.

  • Insights Into Market Dynamics: U.S. Silica (SLCA) Shares Show Significant Increase

    Insights Into Market Dynamics: U.S. Silica (SLCA) Shares Show Significant Increase

    During the current-market proceedings today, the equities of U.S. Silica Holdings, Inc. (NYSE: SLCA) have demonstrated a significant 19.41% surge, currently priced at $15.60. This notable fluctuation in the value of SLCA shares ensued subsequent to the dissemination of its financial performance.

    The first-quarter results of U.S. Silica (SLCA) for the period ending on March 31, 2024, have been formally released. U.S. Silica carried out its operational plan with diligence during the first quarter of 2024, generating significant cash flow from operations at the beginning of the fiscal year and setting the firm up for success throughout the duration of 2024.

    Through the successful repricing of its term loan, U.S. Silica effectively reduced its total interest rate by 85 basis points. Additionally, SLCA undertook the repurchase and extinguishment of an additional $25 million of debt. In the domain of Oil & Gas, volumes experienced a 5% sequential increase, albeit U.S. Silica’s profit margins were impacted by marginally lower pricing, primarily attributed to the decrease in natural gas prices.

    Nevertheless, SLCA maintains 80% of its capacity under long-term contractual obligations, with further amendments and extensions inked in the initial quarter. Moreover, U.S. Silica’s novel Guardian frac fluid filtration system, boasting patent-pending status, continues to garner traction in the market.

    Within the Industrial and Specialty Products sector, revenue and volumes witnessed respective sequential increases of 5% and 10%, with margins exhibiting a year-over-year rise of 7%. In the first quarter, U.S. Silica continued to benefit from continuous structural cost reductions by forging many new customer agreements with advantageous pricing.

    Simultaneously, U.S. Silica has finalized a deal to be purchased by funds overseen by Apollo Global affiliates. The deal is purely cash and values the company at an enterprise value of about $1.85 billion. Due to the upcoming transaction with Apollo Funds, U.S. Silica has decided against holding a conference call for earnings.

  • Behind The Uptrend: Understanding Zura Bio (ZURA) Stock Surge

    Behind The Uptrend: Understanding Zura Bio (ZURA) Stock Surge

    The shares of Zura Bio Limited (NASDAQ: ZURA) are currently witnessing a remarkable surge, demonstrating a significant increase of 20.17% during the current trading session, reaching a value of $4.35. This substantial uptrend in the price of ZUR stock follows recent equity actions, as there is no immediate discernible catalyst directly responsible for this surge.

    Last week, Zura Bio (ZURA) entered into subscription agreements for a private placement anticipated to generate gross proceeds of around $112.5 million, before factoring in placement agent fees and offering expenses. This Private Placement is spearheaded by Access Biotechnology and a prominent institutional investor specializing in life sciences, with participation from other new and existing investors.

    Notable participants include Deep Track Capital, RA Capital Management, Great Point Partners, LLC, Suvretta Capital, funds managed by Allostery Investments LP, Armistice Capital, and other significant investment management entities.

    Zura Bio has agreed to sell about 20.1 million Class A ordinary shares at a price per share of $3.108 under the terms of the deal. Additionally, for some investors, the company will purchase pre-funded warrants that can be used to buy up to 16.1 million Class A ordinary shares at a price per warrant of $3.107.

    Pre-funded warrants are instantly exercisable and will remain so until they are completely exercised. The exercise price of each warrant is $0.001 per common share. The Private Placement is being executed in compliance with relevant Nasdaq regulations and has been priced to meet the “Minimum Price” stipulation.

    The closure of the private placement is expected on April 22, 2024, subject to customary closing conditions being met. The expected proceeds from the private placement are intended to bolster the expedited development of tibulizumab (ZB-106).

    This encompasses the planned Phase 2 clinical trial in systemic sclerosis (SSc), the commencement of a Phase 2 trial assessing tibulizumab for the treatment of hidradenitis suppurativa (HS), and general corporate undertakings. The combination of projected net proceeds with existing cash reserves is anticipated to sustain operations through 2027.

  • Tracking The Ascendancy Of Innodata (INOD) Stock On The US Markets

    Tracking The Ascendancy Of Innodata (INOD) Stock On The US Markets

    In the current trading session, Innodata Inc. (NASDAQ: INOD) is witnessing a remarkable upsurge in its stock value on the US stock charts. The company has recorded a notable increase of 9.41%, with its share price climbing to $6.28 as per the latest check.

    This rise in INOD shares follows the receipt of an accolade from a prominent big tech client. Innodata (INOD) has announced today that it has secured three substantial language model (LLM) development projects from one of its established “Magnificent Seven” Big Tech clients.

    Innodata foresees that these new initiatives, upon full implementation, will collectively generate approximately $20 million in additional annualized run rate revenue. Before these recent awards, the customer’s annualized run rate revenue stood at about $23 million.

    Innodata anticipates finalizing an amendment to its agreement with this client to reflect these new projects in the coming weeks. Work has already commenced on these freshly awarded endeavors. Through this latest recognition, Innodata envisions potential avenues for further expansion in 2024.

    The client consistently lauds Innodata’s high-caliber, large-scale, bespoke data solutions for their LLMs, emphasizing the invaluable partnership with Innodata greatly appreciated by their AI engineering teams. Innodata caters to major tech firms by offering scalable data services for optimizing LLMs, alongside LLM evaluation services.

    By the conclusion of 2023, Innodata had secured five of the Magnificent Seven as clients for its LLM services. Notably, two of these Magnificent Seven, including the aforementioned client, made significant revenue contributions in 2023. In Q4-2023, a third Magnificent Seven client also played a role in revenue growth, and Innodata continued to scale up its services for this client in Q1-2024.

    In its earnings release for Q4/FY2023 on February 22, 2024, Innodata expressed optimism about revenue growth with these three clients in 2024, as well as confidence in making substantial progress with the remaining two signed Magnificent Seven clients during the same period.

  • Market Reacts: Ribbon Communications (RBBN) Stock Climbs Post-Results

    Market Reacts: Ribbon Communications (RBBN) Stock Climbs Post-Results

    Following the release of its financial outcomes today, Ribbon Communications Inc. (NASDAQ: RBBN) observes an ascent in its stock position on the US market. At the latest scrutiny during the current trading session, RBBN shares exhibited a rise of 31.13%, reaching $3.37.

    Ribbon Communications (RBBN) unveiled its financial performance for the initial quarter of 2024 today. Within its IP Optical Networks division, sales marked a year-on-year surge for the seventh consecutive quarter, witnessing a 9% upsurge from the preceding year.

    This elevation can be attributed to diminished product expenses and a robust regional assortment, contributing to the segment’s gross margin surpassing the 40% mark once more. The company has showcased a progression in its profitability compared to the previous year, surpassing the upper limit of its projected figures.

    Furthermore, sales in the EMEA region demonstrated resilience across both Service Provider and Critical Infrastructure sectors, with a notable 24% year-on-year augmentation. Despite a downturn in Cloud & Edge sales during the first quarter, Ribbon Communications has acknowledged a nadir in U.S. Tier One Service Provider expenditures.

    Anticipating the introduction of the new multi-year Verizon Network Modernization initiative, a resurgence in broader Service Provider expenditures, and sustained expansion in the Enterprise sector, including new U.S. Federal ventures, RBBN foresees a revival in growth for its Cloud & Edge segment.

    In a separate announcement today, Ribbon Communications divulged intentions for a substantial network modernization endeavor with Verizon, aimed at phasing out legacy TDM switching platforms and substituting them with contemporary cloud-based technologies.

    Verizon’s objective is to furnish its clientele with state-of-the-art technologies while concurrently enhancing operational cost-effectiveness and advancing sustainability efforts in power consumption.

    The forthcoming network enhancements facilitated by Ribbon Communications will enable Verizon to promptly retire outdated central office equipment, thereby enhancing the overall quality and reliability of its services, while concurrently mitigating its environmental impact.

    The collaboration will enable Verizon to consolidate and supplant equipment with energy-efficient, software-centric platforms, while retaining full feature functionality.

  • Breaking Down The Momentum: B. Riley Financial (RILY) Stock’s Significant Surge

    Breaking Down The Momentum: B. Riley Financial (RILY) Stock’s Significant Surge

    1. Riley Financial, Inc. (NASDAQ: RILY) is witnessing a significant surge in its stock performance amidst current market session, with an impressive 39.43% rise to $30.28. This uptick in RILY stock on the US stock charts is driven by the submission of its much-awaited financial report to the regulatory body.
    2. Riley Financial (RILY) has formally declared the submission of its Annual Report on Form 10-K for the fiscal year concluded on December 31, 2023. Expressing gratitude to various stakeholders for their enduring trust, backing, and forbearance during the finalization of its Annual Report, B. Riley Financial acknowledged that its overall business performance has remained robust since the conclusion of the fiscal year.

    In the realm of small and mid-cap valuations, there exists considerable attractiveness, prompting the company to intensify its efforts in bolstering its position as a frontrunner in furnishing financial services and capital solutions to this underserved sector.

    Since the close of the fiscal year, B. Riley Financial has welcomed seasoned talent, explored promising new ventures, liquidated several others, retired $115 million of its outstanding bonds, and alleviated additional indebtedness by approximately $55 million. The ongoing strategic evaluation of Great American Group is proceeding as planned.

    Furthermore, as delineated in the Company’s 2023 Annual Report, the Audit Committee of the Company’s Board of Directors enlisted Winston & Strawn LLP as independent counsel to aid in conducting an inquiry into the historical relationship between the Company (and its affiliates) and Brian Kahn (and his affiliates), alongside certain associated allegations raised against the Company by specific short sellers.

    The outcomes of the independent inquiry affirmed that B. Riley Financial and its executives were not implicated in, nor had knowledge of, any of the purported misconduct involving Mr. Kahn or any of his affiliates. This independent inquiry was conducted subsequent to the Company’s disclosure on February 22, 2024, regarding the internal review conducted with the assistance of Sullivan & Cromwell LLP as external counsel.

  • Amesite (AMST) Unveils Game-Changing App: Market Reacts!

    Amesite (AMST) Unveils Game-Changing App: Market Reacts!

    Following the proclamation of the inauguration of a novel application today, the shares of Amesite Inc. (NASDAQ: AMST) are soaring during the current trading session. As per the latest update, AMST shares are experiencing a surge of 53.50% on the US charts, reaching $3.07.

    Amesite (AMST) has unveiled the beta version of NurseMagic today, an innovative and exclusive application tailored for nurses. This fresh web-based application harnesses the power of Artificial Intelligence (AI) to furnish practical and user-friendly tools for over 5.2 million nurses, streamlining their daily responsibilities for enhanced efficiency.

    Moreover, in its capacity as a Joint Provider with PACE, it also delivers convenient, accredited Continuing Education (CE) programs to nurses through the app, facilitating compliance with licensure requirements. NurseMagic boasts a range of features, including MedDecode, which swiftly translates medical jargon into plain language; Professional Email Generator, enabling rapid composition of work-related emails.

    It also incorporates CareTalk, aiding nurses in communicating effectively and empathetically with patients; and Wellness Break, guiding nurses on effective breaks during their shifts. Other functionalities comprise MedExplainer, allowing nurses to elucidate medical procedures to patients; and Image-to-Text, converting images into text for seamless comprehension and communication.

    MedUverse offers vital information about medications, while NurseTea collects real-time feedback via surveys shared within the community. AI stands as an indispensable ally in the realm of nursing, augmenting the intrinsic human facets of patient care with cutting-edge technology.

    NurseMagic is conceived with the vision that AI complements nurses, enabling them to allocate more attention to patient welfare and less to mundane tasks, thereby enriching their professional practice on a daily basis. The launch of applications affords us a direct conduit to significantly broader audiences.

    Amesite is committed to furnishing every nurse worldwide with tools that furnish prompt, validated information, addressing the constraints on their time while capitalizing on their expertise. Amesite aims to forge partnerships in this sector, offering professional learning opportunities directly within the app, with further announcements slated for the rollout of additional features.